Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 18, 2026, 5:26 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 132 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Kaposi Sarcoma Clear all
Completed Phase 1 Interventional

Combination Chemotherapy Plus Filgrastim in Treating Patients With Advanced Solid Tumors

NCT00014456
View directory record Official record
Conditions
Bladder Cancer, Breast Cancer, Carcinoma of Unknown Primary, Esophageal Cancer, Gastric Cancer, Head and Neck Cancer, Lung Cancer, Melanoma (Skin), Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Sarcoma
Interventions
filgrastim, docetaxel, gemcitabine hydrochloride
Biological · Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Aug 27, 2013 · Synced Sep 18, 2026, 5:26 PM EDT
Completed Phase 2 Interventional

Liposomal Doxorubicin and Interleukin-12 in Treating Patients With AIDS-Related Kaposi's Sarcoma

NCT00020449
View directory record Official record
Conditions
Sarcoma
Interventions
recombinant interleukin-12, paclitaxel, pegylated liposomal doxorubicin hydrochloride
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 18, 2013 · Synced Sep 18, 2026, 5:26 PM EDT
Completed Phase 3 Interventional

A Randomized Phase III Clinical Trial of Daunoxome Versus Combination Chemotherapy With Adriamycin/Bleomycin/Vincristine (ABV) in the Treatment of HIV-Associated Kaposi's Sarcoma.

NCT00002093
View directory record Official record
Conditions
Sarcoma, Kaposi, HIV Infections
Interventions
Daunorubicin (liposomal), Bleomycin sulfate, Vincristine sulfate, Doxorubicin hydrochloride
Drug
Lead sponsor
Nexstar Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
13
States / cities
Tucson, Arizona • Los Angeles, California • Palm Springs, California + 9 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 18, 2026, 5:26 PM EDT
Completed Phase 1 Interventional

Twins Study of Gene Therapy for HIV Infection

NCT00001535
View directory record Official record
Conditions
Acquired Immunodeficiency Syndrome, HIV Infection, Kaposi's Sarcoma
Interventions
Syngeneic Lymphocytes (CD4+) Cultured with OKT3 (Ortho) and Interleukin-2 (Chiro
Drug
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
Not listed
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 7, 2008 · Synced Sep 18, 2026, 5:26 PM EDT
Completed Phase 2 Interventional

Halofuginone Hydrobromide in Treating Patients With HIV-Related Kaposi's Sarcoma

NCT00064142
View directory record Official record
Conditions
AIDS-related Kaposi Sarcoma, Recurrent Kaposi Sarcoma
Interventions
halofuginone hydrobromide, placebo, laboratory biomarker analysis, pharmacological study
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
16 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 4, 2013 · Synced Sep 18, 2026, 5:26 PM EDT
Terminated Phase 1 Interventional

Liposomal Daunorubicin in Treating Patients With HIV-Related Kaposi's Sarcoma

NCT00427414
View directory record Official record
Conditions
Sarcoma
Interventions
liposomal daunorubicin citrate
Drug
Lead sponsor
AIDS Malignancy Consortium
Network
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 28, 2015 · Synced Sep 18, 2026, 5:26 PM EDT
Completed Phase 1 Interventional

A Phase I Study of AZT and Human Interferon Alpha (Recombinant Alpha-2A and Lymphoblastoid) in the Treatment of AIDS-Associated Kaposi's Sarcoma

NCT00000725
View directory record Official record
Conditions
Sarcoma, Kaposi, HIV Infections
Interventions
Interferon alfa-2a, Zidovudine, Interferon alfa-n1
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1990
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Sep 18, 2026, 5:26 PM EDT
Completed Phase 2 Interventional Results available

Evaluation of Tc 99m Tilmanocept Localization in Primary Cutaneous Kaposi's Sarcoma and Lymphatic Drainage by SPECT/CT

NCT02201420
View directory record Official record
Conditions
Kaposi's Sarcoma
Interventions
Tc 99m tilmanocept
Drug
Lead sponsor
Navidea Biopharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 26, 2016 · Synced Sep 18, 2026, 5:26 PM EDT
Completed Phase 2 Interventional

High-dose ICE With Amifostine

NCT00003657
View directory record Official record
Conditions
Bladder Cancer, Brain and Central Nervous System Tumors, Carcinoma of Unknown Primary, Extragonadal Germ Cell Tumor, Head and Neck Cancer, Kidney Cancer, Lung Cancer, Ovarian Cancer, Sarcoma, Testicular Germ Cell Tumor, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
filgrastim, Amifostine, Carboplatin, Etoposide, Ifosfamide, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2002
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 19, 2017 · Synced Sep 18, 2026, 5:26 PM EDT
Completed Phase 2 Interventional

Nicotine Skin Patch in Treating Patients With Kaposi's Sarcoma

NCT00295984
View directory record Official record
Conditions
Sarcoma
Interventions
nicotine
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 78 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 19, 2013 · Synced Sep 18, 2026, 5:26 PM EDT
Active, not recruiting Phase 1 Interventional

Pomalidomide in Combination With Liposomal Doxorubicin in People With Advanced or Refractory Kaposi Sarcoma

NCT02659930
View directory record Official record
Conditions
Kaposi Sarcoma
Interventions
liposomal doxorubicin, pomalidomide
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 120 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Sep 18, 2026, 5:26 PM EDT
Completed Phase 1 Interventional

MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma

NCT00020579
View directory record Official record
Conditions
Cancer
Interventions
entinostat
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
3
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 14, 2012 · Synced Sep 18, 2026, 5:26 PM EDT
Active, not recruiting Phase 2 Interventional

Pomalidomide Treatment in Patients With Kaposi Sarcoma

NCT04577755
View directory record Official record
Conditions
Skin Kaposi Sarcoma
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Pomalidomide, X-Ray Imaging
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
15
States / cities
La Jolla, California • Miami, Florida • Chicago, Illinois + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2026 · Synced Sep 18, 2026, 5:26 PM EDT
Completed Phase 2 Interventional Results available

A Study to Investigate ALDOXORUBICIN in HIV-infected Subjects With Kaposi's Sarcoma

NCT02029430
View directory record Official record
Conditions
Kaposi's Sarcoma, HIV Positive, AIDS
Interventions
50 mg/m2 aldoxorubicin, 100 mg/m2 aldoxorubicin, 150 mg/m2 aldoxorubicin
Drug
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Jun 10, 2024 · Synced Sep 18, 2026, 5:26 PM EDT
Completed Not applicable Interventional

124I-FIAU Imaging in EBV and KSHV Associated Cancers

NCT00982449
View directory record Official record
Conditions
Hodgkin Lymphoma, Non Hodgkin Lymphoma, Kaposi's Sarcoma, Gastric Cancer, Nasopharyngeal Cancer
Interventions
FIAU-PET-CT-2, FIAU-PET-CT-4
Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 16, 2018 · Synced Sep 18, 2026, 5:26 PM EDT
Completed Phase 2 Interventional Results available

Tocilizumab for KSHV-Associated Multicentric Castleman Disease

NCT01441063
View directory record Official record
Conditions
Castleman Disease, Multicentric Castleman Disease, Giant Lymph Node Hyperplasia
Interventions
Zidovudine, Tocilizumab, Valganciclovir (VGC)
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 26, 2020 · Synced Sep 18, 2026, 5:26 PM EDT
Terminated Not applicable Interventional

Infrared Thermography in Finding Skin Lesions in Patients With Kaposi's Sarcoma

NCT00265902
View directory record Official record
Conditions
Sarcoma
Interventions
diagnostic imaging
Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 19, 2019 · Synced Sep 18, 2026, 5:26 PM EDT
Recruiting Phase 2 Interventional

Propranolol for the Treatment of Kaposi Sarcoma in Adults

NCT06445166
View directory record Official record
Conditions
Kaposi Sarcoma
Interventions
Propranolol Hydrochloride
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced Sep 18, 2026, 5:26 PM EDT
Completed Phase 2 Interventional

Phase II Evaluation of Low-Dose Oral Etoposide for the Treatment of Relapsed or Progressed AIDS-Related Kaposi's Sarcoma After Systemic Chemotherapy

NCT00000807
View directory record Official record
Conditions
Sarcoma, Kaposi, HIV Infections
Interventions
Etoposide
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years and older
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 2000
U.S. locations
20
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2021 · Synced Sep 18, 2026, 5:26 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Pomalidomide for Kaposi Sarcoma in People With or Without HIV

NCT01495598
View directory record Official record
Conditions
Kaposi Sarcoma, Sarcoma, Kaposi
Interventions
Pomalidomide
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 31, 2022 · Synced Sep 18, 2026, 5:26 PM EDT
Recruiting Phase 1Phase 2 Interventional

Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma

NCT04941274
View directory record Official record
Conditions
Kaposi Sarcoma
Interventions
Abemaciclib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 18, 2026, 5:26 PM EDT
Withdrawn No phase listed Observational

Prospective Study of Lymphoproliferative Diseases

NCT01704742
View directory record Official record
Conditions
Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma
Interventions
Not listed
Lead sponsor
West Virginia University
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Nov 7, 2016 · Synced Sep 18, 2026, 5:26 PM EDT
Recruiting Phase 1 Interventional

Study of SGR-1505 in Mature B-Cell Neoplasms

NCT05544019
View directory record Official record
Conditions
Mature B-Cell Neoplasm, Non Hodgkin Lymphoma, DLBCL, Waldenstrom Macroglobulinemia, MALT Lymphoma, Follicular Lymphoma, Pediatric-Type Follicular Lymphoma, IRF4 Gene Rearrangement, EBV-Positive DLBCL, Nos, Burkitt Lymphoma, Plasmablastic Lymphoma, High-grade B-cell Lymphoma, Primary Cutaneous Follicle Center Lymphoma, Primary Effusion Lymphoma, Mantle Cell Lymphoma, DLBCL Germinal Center B-Cell Type, Primary Mediastinal Large B Cell Lymphoma, T-Cell/Histiocyte Rich Lymphoma, ALK-Positive Large B-Cell Lymphoma, Primary Cutaneous Diffuse Large B-Cell Lymphoma, Splenic Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, Nodal Marginal Zone Lymphoma, HHV8-Positive DLBCL, Nos, Lymphoplasmacytic Lymphoma, Duodenal-Type Follicular Lymphoma
Interventions
SGR-1505
Drug
Lead sponsor
Schrödinger, Inc.
Industry
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
16
States / cities
Gilbert, Arizona • Newark, Delaware • Pompano Beach, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Sep 18, 2026, 5:26 PM EDT
Terminated Phase 2 Interventional

A Phase II Trial of COL-3 in Patients With HIV Related Kaposi's Sarcoma

NCT00020683
View directory record Official record
Conditions
AIDS-related Kaposi Sarcoma, HIV Infection
Interventions
incyclinide, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 17, 2018 · Synced Sep 18, 2026, 5:26 PM EDT